Buy Rating for Janux Therapeutics Amidst Competitive Landscape and Advancements in Masked T-cell Engagers
JonesTrading analyst Soumit Roy has maintained their bullish stance on JANX stock, giving a Buy rating on December 27.Stay Ahead of the ...
aTyr Pharma: Interesting Drug, Difficult Target Market
Tyr Pharma's stock surged on positive data for pulmonary sarcoidosis treatment, but cash balance risk keeps investors ...
Hosted on MSN2d
Cantor Fitzgerald Initiates Coverage of aTyr Pharma (ATYR) with Overweight Recommendation
Fintel reports that on January 6, 2025, Cantor Fitzgerald initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a Overweight ...
This Toast Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including ...
Atyr PHARMA (NASDAQ:ATYR) Now Covered by Cantor Fitzgerald
Equities research analysts at Cantor Fitzgerald started coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research report issued to clients and investors on Monday,Briefing.com ...
aTyr Pharma initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of aTyr Pharma (ATYR) with an Overweight rating. aTyr Pharma’s lead drug Efzofitimod is in two trials for ...